RESULTS:
The number of instances when 3 or more results in a disease category had biases greater than the limits of acceptability was 28 of 57 (49%) for Jaffe and 14 of 76 (18%) for enzymatic procedures. For the aggregate group of 59 diabetes samples with increased ␤-hydroxybutyrate, glucose, or glycosylated hemoglobin (Hb A 1c ), the enzymatic procedures had 10 biased results of 236 (4.2%) compared with 89 of 177 (50.3%) for the Jaffe procedures, and these interferences were highly procedure dependent. For supplemented sera, interferences were observed in 11 of 24 (46%) of groups for Jaffe and 8 of 32 (25%) of groups for enzymatic procedures and were different at low or high creatinine concentrations.
CONCLUSIONS: There were differences in both magnitude and direction of bias among measurement procedures, whether enzymatic or Jaffe. The influence of interfering substances was less frequent with the enzymatic procedures, but no procedure was unaffected. The details of implementation of a method principle influenced its susceptibility to potential interfering substances.
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The 2006 report from the National Kidney Disease Education Program (NKDEP) 7 Laboratory Working Group (LWG) (1 ) highlighted the need for improved standardization of routine measurements of serum and plasma creatinine (2, 3 ) . Although calibration was emphasized in the report, interferencerelated bias was not overlooked. In recommendations for in vitro diagnostics (IVD) manufacturers, the report stated, "IVD manufacturers must address analytical nonspecificity bias in current routine serum creatinine methods."
Standardization of creatinine measurement procedures with calibrations traceable to isotope dilution mass spectrometry (IDMS) reference measurement procedures has largely been accomplished for major manufacturers in North America, as evidenced in external quality assessment schemes using commutable samples. For example, in the February 2010 College of American Pathologists (CAP) Creatinine Accuracy Calibration Verification/Linearity (LN24) Survey, 11 method groups had mean bias of 0% (range Ϫ5.8% to 7.7%) vs NIST reference measurement procedure values for creatinine concentrations between 0.77 mg/dL (68 mol/L) and 4.09 mg/dL (362 mol/L), and the CV for all participants (n ϭ 372) was between 6.6% and 2.9% (4 ) .
The NKDEP LWG and the International Federation of Clinical Chemistry and Laboratory Medicine Working Group on Glomerular Filtration Rate Assessment designed the present study to obtain contemporary data for use in establishing specificity performance recommendations for serum creatinine measurement procedures.
Materials and Methods

SAMPLES EXAMINED
Individual patient samples. The study was approved by the respective institutional review boards at both clinical sample collection locations: Virginia Commonwealth University (VCU) and University of Utah Associated Regional University Pathologists (ARUP) laboratories.
Sample handling and storage conditions were consistent with published information on stability of creatinine in human serum or plasma (5 ) . Individual patient serum or heparinized plasma samples were collected in accordance with standard laboratory practices. Residual samples submitted for laboratory testing were stored up to 8 h at room temperature then up to 14 days at 2-4°C before division into aliquots and frozen storage at Ϫ70°C (VCU) or up to 24 h at room temperature then up to 30 days at Ϫ20 to Ϫ30°C before thawing, aliquoting, and refreezing at Ϫ70°C (ARUP). Five 0.25-mL aliquots, in 1.2-mL cryovials (VWR International) were prepared from each residual sample and stored at ϽϪ70°C until being shipped on solid CO 2 to participating manufacturers and the designated comparison measurement procedure (DCMP) laboratory. Samples were stored at ϽϪ70°C at each participating laboratory until being measured between January and March 2009.
We selected samples to obtain up to 20 individual serum or plasma samples in each of 19 disease categories established to have either known concentrations of, or a high probability to contain, substances suspected as potential interferents in creatinine measurement procedures (1 ). Samples were not pooled, except those with increased pyruvate were obtained from pooled whole blood that was incubated at room temperature 24 -48 h before centrifugation. We identified the selected samples in each category (Table 1) on the basis of previously measured laboratory values, patient location consistent with 1 or more of the selected disease categories, or medical record review. In addition, for a control group, we collected samples from 20 nondiseased individuals (laboratory staff volunteers) who were not using any prescription or over-the-counter pharmaceutical or dietary supplement products.
Samples spiked with potential interfering substances. Serum with a creatinine concentration of 0.90 mg/dL (80 mol/L) was obtained from a healthy male volunteer, age 48 years. Half was supplemented with a solution of 150 mg/dL (13.26 mmol/L) creatinine hydrochloride (Sigma Aldrich) dissolved in water to a final creatinine concentration of 3.80 mg/dL (336 mol/L). Candidate interfering substances were added as described in the Supplemental Data, which accompanies the online version of this article at http://www.clinchem.org/content/vol58/issue2.
INSTRUMENTS AND MEASUREMENT PROCEDURES
Designated comparison measurement procedure. We measured serum or plasma creatinine by liquid chromatography/IDMS (LC-IDMS) based on the method described by Preiss et al. (6 ) . Procedural details are provided in the online Supplemental Data.
Commercial clinical laboratory measurement procedures. Participating manufacturers and respective measurement procedures were as follows: Beckman Coulter Synchron Unicel enzymatic (E1) and Jaffe (J1), Ortho Clinical Diagnostics Vitros 5,1 FS Chemistry System enzymatic (E2), Roche Diagnostics Integra enzymatic (E3) and Jaffe (J2), and Siemens Dimension RxL enzymatic (E4) and Jaffe (J3). Characteristics of the commercial creatinine procedures, and details of the protocol for preanalytical sample handling and creatinine measurement at the participating manufacturers' laboratories, are provided in online Supplemental Table S1 .
Characterization of additional analytes. Procedures for measurement of concentrations of additional analytes used for selection and characterization of patient samples were as described in Table 1 , footnote a.
STATISTICAL PROCEDURES
For each commercial procedure and the DCMP, we used the mean of quadruplicate creatinine measurements on each sample for all statistical analyses and comparisons.
For samples supplemented with interfering substances, we calculated percentage recovery as the creatinine concentration at each concentration of the interferent divided by the creatinine concentration of the unspiked sample, multiplied by 100. Percentage bias was the percentage recovery minus 100. We used standard linear or polynomial regression to estimate the relationship between percentage recovery of creatinine and the concentration of an interferent.
For individual patient samples, we calculated bias as the difference from the DCMP creatinine concentration. On the basis of the distribution of biases observed for the samples from healthy controls (Fig. 1, A and B) , the criteria for presence of a nonspecificity bias was defined as the larger of 0.10 mg/dL (8.8 mol/L) or 10%. For the rationale for these criteria, see online Supplemental Data: Additional Statistical Considerations. 
Results
CALIBRATION TRACEABILITY
We assessed trueness for each creatinine measurement procedure by recovery of the certified concentration with Note that 1 sample with creatinine 8.35 mg/dL is not shown in C but had biases of 0.10, Ϫ0.02, Ϫ0.28, and Ϫ0.56 for procedures E3, E4, E2, and E1, respectively, nor in panel D but had biases of 0.20, 0.20, and 0.14 mg/dL for procedures J1, J2, and J3. Symbols: ‚, procedure E1 or J1; ٗ, procedure E2 or J2; E, procedure E3 or J3; ϫ, procedure E4. The lines indicate the criteria used for a meaningful nonspecificity bias. Multiply by 88.4 to convert creatinine to mol/L. Tables S2 and S3 for additional data on the calibration traceability of the DCMP.
For the commercial procedures, bias was Յ5.9% for SRM 967-1 and Յ3.8% for SRM 967-2. Four of 7 means were within the uncertainty interval of SRM 967-1 (see online Supplemental Fig. S3A ). The Ϯ2 SD ranges for 2 means overlapped the uncertainty interval, and the Ϯ2 SD range for 1 mean (procedure E4) was just outside the uncertainty interval. For SRM 967-2 (see online Supplemental Fig. S3B ), 3 of 7 means were within the uncertainty interval, the Ϯ2 SD ranges for 3 means overlapped the uncertainty interval, and the Ϯ2 SD range for 1 mean (procedure E1) was just outside the uncertainty interval.
For all commercial procedures, mean biases for 137 of 140 results (98%) in the healthy individuals were within 0.10 mg/dL (8.8 mol/L) of the DCMP (Fig. 1,  A and B) , and the mean biases for each individual procedure ranged from Ϫ5.5% to 5.8%, further supporting calibration traceability to IDMS reference measurement procedures (8 ) . With either the mean bias with SRM 967-1 or the mean bias for healthy individuals, in conjunction with CV estimates based on either the within-procedure imprecision for SRM 967-1 obtained in this study or with the within-procedure/amonglaboratories CV from the CAP Comprehensive Chemistry Survey C-B (2011), the total allowable error of all commercial procedures was within the recommendations of the NKDEP LWG (1 ) (see online Supplemental Fig. S4 ).
Therefore, we used no corrections for calibration biases in any of the commercial procedures in the data analysis.
INTERFERING SUBSTANCES SUPPLEMENTED INTO SERUM
Owing to concerns about their stability, acetoacetate, acetone, ascorbate, and pyruvate were supplemented into serum with within-reference interval and increased creatinine concentrations. The maximum percent biases observed for each supplemented interferent at each concentration of creatinine are summarized in Table 2 , and interferographs are shown in online Supplemental Data Figs. S5-S8.
INDIVIDUAL SAMPLES FROM CLINICAL CATEGORIES
Difference plots for the biases observed between routine creatinine measurement procedures and the DCMP are shown for apparently healthy controls and hemolyzed and delayed sample processing (Fig. 1) ; increased glucose, increased glycosylated hemoglobin (Hb A 1c ), and increased ␤-hydroxybutyrate (Fig. 2) ; and low albumin, low total protein, and high total protein (Fig. 3) clinical sample categories. The biases observed for the other clinical sample categories are shown in online Supplemental Figs. S9 -S19. Table 3 summarizes results for all clinical sample categories by measurement procedure. For 1 or more of the Jaffe procedures, Ն3 biased creatinine values per clinical sample group were observed for the increased ␤-hydroxybutyrate, increased glucose, increased Hb A 1c , cardiovascular disease, cephalosporin, dobutamine, lidocaine, increased bilirubin, delayed sample processing, hemolyzed, lipemic, low albumin, high total protein, and post-kidney transplant groups. For 1 or more of the enzymatic procedures, Ն3 biased creat- 
Fig. 2. Creatinine measurement bias vs DCMP for individual serum or plasma samples from the groups with increased glucose (A and B), increased Hb A 1c (C and D), and increased ␤-hydroxybutyrate (E and F).
Note that 1 sample with creatinine 10.11 mg/dL is not shown in panel E but had biases of 0.39, Ϫ0.31, Ϫ0.48, and Ϫ0.96 for procedures E2, E3, E4, and E1, respectively, nor in panel F but had biases of 0.33, 0.02, and Ϫ1.27 mg/dL for procedures J3, J1, and J2. ‚, procedure E1 or J1; ٗ, procedure E2 or J2; E, procedure E3 or J3; ϫ, procedure E4. The lines indicate the criteria used for a meaningful nonspecificity bias. Multiply by 88.4 to convert creatinine to mol/L.
inine values per clinical sample group were observed for the increased ␤-hydroxybutyrate, dobutamine, lidocaine, increased bilirubin, hemolyzed, lipemic, and high total protein groups. Of the 365 clinical samples, the overall proportion of biased results was 11.7%, 9.0%, 8.8%, and 11.2% for the 4 enzymatic methods and 19.5%, 15.6%, and 35.9% for the 3 Jaffe methods. Overall, more biases were observed for the Jaffe procedures, but findings were inconsistent in terms of occurrence rate, direction, and magnitude of bias (Table 3 , Figs. 1-3 , and online Supplemental Figs. S9 -S19), within a method principle (Jaffe or enzymatic).
Fig. 3. Creatinine measurement bias vs DCMP for individual serum or plasma samples from the low albumin group (A and B), the low total protein group (C and D), and the high total protein group (E and F).
‚, procedure E1 or J1; ٗ, procedure E2 or J2; E, procedure E3 or J3; ϫ, procedure E4. The lines indicate the criteria used for a meaningful nonspecificity bias. Multiply by 88.4 to convert creatinine to mol/L.
Discussion
Calibrations of the LC-IDMS DCMP and the commercial measurement procedures were verified to be traceable to Joint Committee for Traceability in Laboratory Medicine (JCTLM) listed reference measurement procedures and reference materials. Consequently, calibration bias of the commercial creatinine measurement procedures was not a factor in evaluating the influence of potential interfering substances. The serum creatinine concentration influenced the magnitude of specific interferences in our supplementation studies. The interferographs, particularly for the Jaffe procedures, demonstrated substantial interferences at low creatinine concentrations but no interference at high creatinine concentrations. Nearly all of the interferences observed for the Jaffe procedures were positive, with the exception of acetoacetate for procedure J2. The magnitude of the interference observed for the Jaffe procedures was similar for acetone and pyruvate but differed markedly for acetoacetate and ascorbate.
For enzymatic procedures, the magnitude of the interference observed in the supplementation studies was generally smaller than for the Jaffe procedures, but the pattern of interference across procedures was more complicated. For acetoacetate, the interference was positive for 1 enzymatic procedure, negative for 1, and absent for the other 2. No interference was observed for Table 3 . Number of samples in each sample category with a negative (-) or positive (؉) bias >0.10 mg/dL (>8.8 mol/L) or >10%, whichever was greater.
Sample category n
Creatinine measurement procedure acetone with any of the enzymatic procedures. For ascorbate, 2 enzymatic procedures showed negative interference at low creatinine concentrations and 2 showed positive interference at high creatinine concentrations. Procedure E3 showed negative interference at low creatinine concentrations and positive interference at high creatinine concentrations. For pyruvate, 2 procedures showed positive interferences at high creatinine concentrations. Cobbaert et al. (9 ) examined the effects of albumin, hemoglobin A, IgG, and unconjugated bilirubin on enzymatic and Jaffe creatinine procedures by supplementing these substances into serum pools. Those authors found positive creatinine biases from albumin and IgG for Jaffe procedures but not for enzymatic procedures. An important difference in our experimental design was that we selected individual clinical samples containing the potentially interfering substances. However, biases may have been due to presence of the substance used to select the samples or to unknown substances associated with samples in that disease category. We found that 2 of 3 Jaffe procedures exhibited a positive bias with high protein samples and a few samples had a negative bias with 1 Jaffe procedure; we also observed a positive bias with 1 enzymatic procedure. Our findings for patient samples selected for low albumin concentrations showed that 1 Jaffe procedure had a positive bias with 2 samples, 1 Jaffe procedure had a negative bias with 2 samples, and 1 Jaffe procedure had a negative bias with 1 sample and a positive bias with 7 samples. For the high total protein sample category, 1 enzymatic and 2 Jaffe procedures showed positively biased creatinine values. Although we were not able to specifically identify the interfering substances in the clinical samples, our results for samples with protein concentrations not within reference intervals demonstrated that both enzymatic and Jaffe methods were affected and that the influence of interfering substances was complex and dependent on the technical implementation of a measurement procedure.
Previously reported effects of bilirubin on enzymatic and Jaffe procedures for serum creatinine have been contradictory. Cobbaert et al. (9 ) found that enzymatic and some Jaffe procedures demonstrated similar slight positive or negative interferences with unconjugated bilirubin, whereas other Jaffe procedures exhibited Ͼ10% negative interference. Owen et al. (10 ) measured creatinine results for 73 patient samples with bilirubin concentrations of 5.8 -56 mg/dL (99 -958 mol/L) using Roche enzymatic and Jaffe procedures and an LC-IDMS procedure. They found that 49% of creatinine results had Ϫ10% to Ϫ35% bias for the enzymatic procedure and, for the Jaffe procedure, 1 result had Ͼ10% bias and 2 results had ϽϪ10% bias. For the high bilirubin patient group in our study, all but 1 sample had bilirubin concentration Ͼ19 mg/dL (Ͼ325 mol/L), and most of these samples were collected from only 3 patients. For 3 of 4 enzymatic procedures and 1 of 3 Jaffe procedures, a large portion of the samples were negatively biased. Interestingly, procedure E2 had only 1 biased result and procedure J1 had no biased results with the increased bilirubin samples. As for protein, our results demonstrated that the influence of bilirubin was complex and dependent on the technical implementation of a measurement procedure.
Delayed separation of serum from cellular components following specimen collection has been reported to cause increased creatinine results with some Jaffe creatinine procedures, likely owing to accumulation of pyruvate (11 ) . For the delayed sample separation category, all 3 Jaffe procedures showed a positive bias with variable numbers of samples. When serum pools were supplemented with pyruvate, all 3 Jaffe procedures demonstrated positive biases at a creatinine concentration of 0.9 mg/dL (80 mol/L) but almost no bias at creatinine 3.8 mg/dL (336 mol/L); 2 of 4 enzymatic procedures had positive biases only at the higher creatinine concentration.
Highly procedure-dependent interferences were observed for the aggregate of 3 sample categories with 59 diabetes patient samples known to have increased ␤-hydroxybutyrate (n ϭ 19), glucose (n ϭ 20), and Hb A 1c (n ϭ 20). All 3 Jaffe procedures had a large number of positively biased results for the glucose category. Procedures J1 and J3 had a large number of positively biased results for the ␤-hydroxybutyrate category, whereas procedure J2 had a smaller number of predominantly negative biases. Procedure J3 had a large number of positive biases for the increased Hb A 1c category, and the other Jaffe procedures had essentially no biases. For the enzymatic procedures, there were 0 -3 samples with biases in each of the diabetes sample categories, suggesting minimal or no specificity issues for these categories. Our data do not identify the root cause for a given bias (e.g., Hb A 1c is likely not the root cause of the bias in the increased Hb A 1c patient group), but these disease categories likely included additional substances that influenced some creatinine procedures. For patients with diabetes, enzymatic procedures appeared to be more suitable than Jaffe procedures.
In the cardiovascular disease group, only the J3 procedure showed positive biases. For the kidney disease patient category, none of the procedures had biased results for the sample categories predialysis, low estimated glomerular filtration rate (eGFR), and high urine protein where creatinine concentrations were higher. For the post-kidney transplant group with lower creatinine concentrations, only procedure J3 had a few positively biased results. For the patient groups for which creatinine is an important biomarker, it appears that properly implemented enzymatic or Jaffe procedures gave satisfactory results.
Lidocaine showed large positive biases in a large number of samples for all enzymatic methods, whereas Jaffe methods had modest biases in a few samples. There was no influence from dopamine. Dobutamine showed positive biases with 2 of 3 Jaffe procedures and negative biases with all enzymatic procedures. Cephalosporin showed positive biases for 2 of 3 Jaffe procedures, with no influence on the enzymatic procedures.
REVIEW OF FINDINGS VS MANUFACTURERS' LABELING
We compared the biases for samples containing known amounts of supplemented interfering substances to interference claims obtained from each manufacturer's instructions for use (IFU). In general, the IFUs did not contain adequate information regarding the effects of interfering substances on the procedures. Acetoacetate, acetone, ascorbate, and pyruvate are well-known interferents in creatinine measurements (12 ) . Nonetheless, only 4 of 7 IFUs had interference claims for acetoacetate, none had claims for acetone, 5 had claims for ascorbate, and 2 had claims for pyruvate. Of those that did have claims for these interferences, most did not have adequate information to interpret the claims. In many cases, the IFUs did not state the concentrations of interfering substances and/or creatinine concentrations tested. In some cases in which the concentration of interferent was stated, it was substantially lower than that expected to be encountered in diseased patient populations (12) (13) (14) (15) (16) (17) . In addition, the criteria used for evaluation of the effects of interferences were not uniform among manufacturers.
STRENGTHS AND LIMITATIONS
Strengths of this investigation were inclusion of a substantial number of individual patient samples representing diverse clinical conditions selected to have a high probability to contain potentially interfering substances and a control group of samples from healthy individuals. This approach eliminated any noncommutability artifacts from influencing results and included a range of both exogenous pharmaceutical and endogenous metabolic substances. Several labile metabolic substances were examined by supplementing a single donor serum to ensure the substances were present in the samples tested. The LC-IDMS DCMP and the commercial measurement procedures were validated to have calibration traceable to JCTLM listed reference measurement procedures. IDMS technology is considered the best available to be free from the influence of interfering substances. All measurements were made in quadruplicate to minimize the influence of measurement imprecision.
Limitations of this study were that we were unable to include all manufacturers because of limited volumes available (as residual samples from clinical laboratories). The clinical samples were selected to have a high probability to contain various interfering substances; however, the identity and concentrations of the substances responsible for a given interference were either unknown or only partially known based on the selection parameters. In addition, the number of samples included in each clinical category was relatively small (approximately 20), and in some cases, different samples from the same individual were included more than once in a clinical category. The clinical samples were not handled uniformly before aliquoting and freezing, with variable time spent at room temperature, refrigerated, or frozen, with possible metabolic changes or loss of labile components (e.g., dopamine and dobutamine). In addition, samples collected at ARUP were thawed, aliquoted, and refrozen. Given previously published findings that creatinine in serum or plasma is a stable measurand under common sample storage conditions (5 ), it is unlikely that sample handling or storage contributed to underestimation of creatinine in this study. However, the consequence of sample handling and storage variations on substances that may interfere with creatinine measurements is unknown, and may have led to underestimation of bias in certain disease categories. Finally, the serum creatinine concentration interval examined in the patient samples selected for this study was inadequate to address measurement specificity issues at creatinine concentrations typically found in pediatric patients between the ages of 2 months and 10 years, in whom values are usually Ͻ0.6 mg/dL (50 mol/L) (18 ) .
Conclusions
Overall, the influence of interfering substances was less frequent with enzymatic procedures than with Jaffe procedures, but no procedure was unaffected by the interfering substances or disease categories examined. There were differences in both magnitude and direction of bias among measurement procedures within a given method principle, enzymatic or Jaffe, indicating that influence of interfering substances depended on details of implementation of the method principle. With the exception of the diabetic disease category, which showed substantially more frequent influence of interfering substances with Jaffe procedures than with enzymatic procedures, no general conclusions regarding Jaffe or enzymatic technologies can be drawn. Supplemented interferents had greater influence at creatinine concentrations within reference intervals than at higher concentrations, highlighting the importance of evaluating interference at more than 1 concentration of the measurand. The results emphasize the need to evaluate interference characteristics in detail with each particular measurement procedure with consideration of the patient populations served.
Manufacturers' labeling and claims for interferences with commercial creatinine measurement procedures had shortcomings in the information provided. It is recommended that manufacturers' claims be based on testing at clinically relevant concentrations of a broad range of potential interferents as well as at 2 or more concentrations of the measurand.
On the basis of the magnitude of biases observed in the healthy controls category, it is recommended that specifications for bias from interfering substances in creatinine measurement procedures should not exceed the larger of 0.1 mg/dL or 10% at a given concentration of creatinine.
